Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S95-S98
DOI: 10.4103/ijmpo.ijmpo_237_17
Original Article

Metastatic Synovial Sarcoma: Experience from a Tertiary Care Center from India

K Govind Babu
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
Rajesh Patidar
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
C Lakshmaiah Kuntegowdanahalli
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
Lokanatha Dasappa
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
Linu Abraham Jacob
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
Suresh Babu
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
AH Rudresha
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
Lokesh N Kadabur
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
LK Rajeev
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
Deepak Koppaka
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
,
Vikas Asati
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Background: Synovial sarcoma represents 8% of all soft-tissue sarcoma (STS). It is a high-grade STS, and 50% of patients develop metastasis. The most common site of metastasis is the lungs, lymph nodes followed by bones. Ifosfamide-based chemotherapy is associated with improved outcome. In this study, we report our experience of metastatic synovial sarcoma according to primary sites, metastatic pattern, and their outcome. Materials and Methods: This was a retrospective observational study carried out at our institute from January 2013 to December 2016. The aim of our study was to evaluate the pattern of metastasis, response to chemotherapy, and survival in patients with metastatic synovial sarcoma. Results: Over a period of 4 years, 43 patients with metastatic synovial sarcoma were diagnosed with median age of 30 years. Nearly 70% of patients had lung metastasis, other site of metastasis were lymph node, bone, and liver. Thirty patients received chemotherapy with a combination of ifosfamide and doxorubicin. The overall response rate was 87% with median progression-free survival of 8 months. Patients with lung only metastasis had better survival compared with nonpulmonary metastatic site (18 months vs. 12 months). The median survival was 18 months. Conclusion: Metastatic synovial sarcoma is chemoresponsive tumor with lung being the most common metastatic site. Patients with lung only metastasis had a better outcome than nonpulmonary metastasis.

Keywords

Metastatic synovial sarcoma - sarcoma - synovial sarcoma


Publication History

Article published online:
24 May 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: A National Cancer Database report. Cancer Med 2014; 3: 1404-15
    CrossrefPubMedGoogle Scholar
  • 2 Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol 2008; 97: 314-20
    CrossrefPubMedGoogle Scholar
  • 3 Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM. et al. Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18: 2087-94
    CrossrefPubMedGoogle Scholar
  • 4 Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998; 2: 401-21
    CrossrefPubMedGoogle Scholar
  • 5 Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013; 153: 71-85
    CrossrefPubMedGoogle Scholar
  • 6 Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: A clinicopathological study of 136 cases. Cancer 1977; 39: 1201-17
    CrossrefPubMedGoogle Scholar
  • 7 Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. Cancer 1965; 18: 613-27
    CrossrefPubMedGoogle Scholar
  • 8 Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS. et al. Synovial sarcoma: Retrospective analysis of 250 patients treated at a single institution. Cancer 2009; 115: 2988-98
    CrossrefPubMedGoogle Scholar
  • 9 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47
    CrossrefPubMedGoogle Scholar
  • 10 Rajeev LK, Patidar R, Babu G, Suresh Babu MC, Lokesh KN, Patil Okaly GV. et al. A rare case of primary synovial sarcoma of lung. Lung India 2017; 34: 545-7
    CrossrefPubMedGoogle Scholar
  • 11 Jain A, Sajeevan KV, Babu KG, Lakshmaiah KC. Chemotherapy in adult soft tissue sarcoma. Indian J Cancer 2009; 46: 274-87
    CrossrefPubMedGoogle Scholar
  • 12 Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E. et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007; 246: 105-13
    CrossrefPubMedGoogle Scholar
  • 13 Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: An analysis of 104 patients treated at the Royal Marsden hospital. Ann Oncol 2005; 16: 437-44
    CrossrefPubMedGoogle Scholar
  • 14 Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B. et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80: 1221-7
    CrossrefPubMedGoogle Scholar
  • 15 Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A. et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010; 46: 72-83
    CrossrefPubMedGoogle Scholar
  • 16 Salah S, Yaser S, Salem A, Al Mousa A, Abu Sheikha A, Sultan I. et al. Factors influencing survival in metastatic synovial sarcoma: Importance of patterns of metastases and the first-line chemotherapy regimen. Med Oncol 2013; 30: 639
    CrossrefPubMedGoogle Scholar
  • 17 Schöffski P. Pazopanib in the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther 2012; 12: 711-23
    CrossrefPubMedGoogle Scholar
  • 18 George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T. et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27: 3154-60
    CrossrefPubMedGoogle Scholar
  • 19 Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organization for Research and Treatment of Cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-32
    CrossrefPubMedGoogle Scholar
  • 20 Deeks ED. Pazopanib: In advanced soft tissue sarcoma. Drugs 2012; 72: 2129-40
    CrossrefPubMedGoogle Scholar
  • 21 van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-86
    CrossrefPubMedGoogle Scholar
  • 22 Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D. et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. Lancet 2016; 388: 488-97
    CrossrefPubMedGoogle Scholar
  • 23 Tawbi HA, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetze S. SARC028 Investigators. et al Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. Journal of Clinical Oncology 2016; 34 (15) 11006-11006
    CrossrefGoogle Scholar